A Phase IIb, 96 Week, Randomized, Partially Double-Blinded, Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of GW873140 in Combination With Combivir (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults

Trial Profile

A Phase IIb, 96 Week, Randomized, Partially Double-Blinded, Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of GW873140 in Combination With Combivir (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Aplaviroc; Efavirenz; Lamivudine/zidovudine
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ASCENT
  • Most Recent Events

    • 20 May 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
    • 18 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top